Clinical trial NCT04161391: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Official title: A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Non Small Cell Lung Cancer
Medullary Thyroid Cancer
RET Gene Mutation
Metastatic Solid Tumor
Advanced Solid Tumor
Keywords: Non small cell lung cancer
Non-small cell lung cancer
NSCLC
Medullary Thyroid Cancer
MTC
RET gene mutation
RET gene alteration
Advanced non small cell lung cancer
Advanced/metastatic disease
lung cancer
lung adenocarcinoma
Metastatic solid tumor
Advanced Solid Tumors
RET gene fusion
RET inhibitor
SRC
TPX-0046
Thyroid cancer
Lead sponsor: Turning Point Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2019-11-13
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.

Detailed description: Phase 1 Dose Escalation and Dose Expansion: To evaluate the overall safety profile, characterize the PK profiles and assess the preliminary efficacy of TPX-0046 in adults subjects with advanced solid tumors harboring oncogenic RET fusions or mutations.

Food Effect Sub-Study: To determine the effect of food on PK of TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring oncogenic RET fusions or mutations.

Phase 2 Efficacy Evaluation: To determine the overall safety and anti-tumor efficacy of TPX-0046 in defined cohorts of subjects with advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 (or age ≥ 20 as required by local regulation).
2. Histological or cytological confirmation of advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations, who either have disease progression on, or are intolerant to standard therapy; OR are ineligible for standard therapy or for whom no standard therapy exists; OR are unlikely to tolerate or derive clinical benefit from standard therapy in the opinion of the Investigator OR have declined standard therapy.
3. ECOG performance status ≤ 1.
4. Existence of measurable or evaluable disease (according to Response evaluation criteria in solid tumors \[RECIST v1.1\] criteria).
5. Subjects with asymptomatic primary CNS tumors or brain metastases are eligible for the study if they meet protocol specified criteria.
6. Adequate organ function.
7. Life expectancy ≥ 12 weeks.

Exclusion Criteria:

1. Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and/or radiotherapy, or chemotherapy.
2. Presence or history of any other primary malignancy within 3 years other than a history of adequately treated basal or squamous cell carcinoma of the skin, or any adequately treated in situ carcinoma.
3. Major surgery within four weeks of the start of therapy.
4. Clinically significant cardiovascular disease (either active or within six months before enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of CTCAE version 5.0 grade ≥ 2.
5. Any of the following cardiac criteria:

   * Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \> 470 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value
   * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \> 250 msec)
   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
6. Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).
7. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
8. Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.
9. Subjects with current or anticipated need for drugs that are sensitive CYP2C9 substrates with narrow therapeutic indices.

Primary outcomes:
measure: Number of Participants With Dose Limiting Toxicities (DLTs) of TPX-0046
timeFrame: 28 days following the first highest dose of the dose regimen administered in Cycle 1
measure: Maximum Tolerated Dose (MTD) of TPX-0046
timeFrame: 28 days following the first highest dose of the dose regimen administered in Cycle 1
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Local Institution - 2129
state: California
city: Orange
country: United States
facility: Local Institution - 2128
state: California
city: Aurora
country: United States
facility: Local Institution - 2122
state: Colorado
city: Denver
country: United States
facility: SCRI - HealthOne Denver
state: Colorado
city: Washington
country: United States
facility: Local Institution - 2126
state: District of Columbia
city: Jacksonville
country: United States
facility: Mayo Clinic - Jacksonville
state: Florida
city: Tampa
country: United States
facility: Local Institution - 2130
state: Florida
city: Atlanta
country: United States
facility: Local Institution - 2127
state: Georgia
city: Chicago
country: United States
facility: University of Chicago Medicine
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Ann Arbor
country: United States
facility: Local Institution - 2124
state: Michigan
city: Detroit
country: United States
facility: Local Institution - 2131
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic - Arizona
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic - Rochester
state: Minnesota
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Philadelphia
country: United States
facility: Local Institution - 2137
state: Pennsylvania
city: Houston
country: United States
facility: Local Institution - 2120
state: Texas
city: Houston
country: United States
facility: Baylor College of Medicine - Baylor Heart Clinic
state: Texas
city: Fairfax
country: United States
facility: Local Institution - 2135
state: Virginia
city: Seattle
country: United States
facility: Local Institution - 2132
state: Washington
city: Seoul
country: Korea, Republic of
facility: Local Institution - 6320
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: